COPPS-2: Colchicine for prevention of post-pericardiotomy syndrome and postoperative atrial fibrillation

180 patients with colchicine 0.5 mg twice daily from 48-72 hs. before surgery versus 180 patients to placebo were randomized. The medication was continued for a month. The aim of the study was to evaluate whether colchicine was able to avoid the post-pericardiotomy syndrome. 

The post pericardiotomy syndrome occurred in 19.4% of patients in the colchicine group versus 29.4% in the placebo group (p <0.05). However considering separately atrial fibrillation or pericardial effusion no significant differences were observed. 

Article

6_stavros_konstantinides_presentacion
Stavros V. Konstantinides
2014-08-31

Original title: Colchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial).

 

More articles by this author

ODYSSEY LONG TERM: Safety and efficacy of long-term alirocumab

This was a prospective, randomized, controlled study comparing monoclonal antibody alirocumab with placebo in patients with hypercholesterolemia and high cardiovascular risk. At 24 weeks...

LISTEN: Rosuvastatin versus atorvastatin in Japanese diabetic patients

The treatment of hyperlipidemia is useful in primary and secondary prevention of chronic heart disease and stroke, particularly in diabetic patients. Many statins may...

ODYSSEY FH I and FH II: Alirocumab in patients with heterozygous familial hypercholesterolemia

The study included patients with a diagnosis of heterozygous familial hypercholesterolemia who were receiving the maximum tolerated dose of randomized statin alirocumab 75 mg...

SIGNIFY: Ivabradine does not reduce events in patients with stable coronary disease

The increase in heart rate in the setting of chronic coronary artery disease is associated with poor prognosis, especially increased risk of acute myocardial...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

TricValve Transcatheter Bicaval Valve System for Severe Tricuspid Insufficiency: Events at One Year

TricValve is the first bicaval valve system to obtain CE-Mark approval. This device heterotopic device eliminates tricuspid insufficiency reflux into the venous system, reducing...

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...